Deerfield Management Company, L.P. (Series C) Black Diamond Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.87 - $4.99 $2.5 Million - $4.34 Million	-869,553 Reduced 48.31%	930,447 $2.67 Million
Q2 2023 Aug 14, 2023	BUY	$1.43 - $6.18 $2.57 Million - $11.1 Million	1,800,000 New	1,800,000 $9.09 Million
Q4 2021 Feb 14, 2022	SELL	$5.18 - $8.48 $3.94 Million - $6.45 Million	-760,128 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.46 - $12.42 $2.43 Million - $3.57 Million	-287,471 Reduced 27.44%	760,128 $6.43 Million
Q1 2021 May 17, 2021	BUY	$22.23 - $34.75 $5.45 Million - $8.52 Million	245,088 Added 30.54%	1,047,599 $25.4 Million
Q3 2020 Nov 16, 2020	BUY	$26.17 - $43.07 $6.97 Million - $11.5 Million	266,510 Added 49.72%	802,511 $24.3 Million
Q1 2020 May 15, 2020	BUY	$18.18 - $39.48 $9.74 Million - $21.2 Million	536,001 New	536,001 $13.4 Million

Others Institutions Holding BDTX

# of Institutions

121

Shares Held

48.8M

Call Options Held

1.84M

Put Options Held

1.93M

T. Rowe Price Investment Management, Inc. Baltimore, MD

10.7M
Shares

$26.4 Million
0.03% of portfolio
Bellevue Group Ag Kuesnacht, V8

8.52M
Shares

$21 Million
0.62% of portfolio
Vestal Point Capital, LP New York, NY

5.03M
Shares

$12.4 Million
1.66% of portfolio
Nea Management Company, LLC Timonium, MD

4.45M
Shares

$10.9 Million
1.48% of portfolio
Black Rock Inc. New York, NY

3.22M
Shares

$7.91 Million
0.0% of portfolio

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $89.4M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account